The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi's flu shot Fluzone HD, respectively. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/novavaxs-covid-flu-combo-vaccine-shows-strong-immune-response-in-trial/121782680